Verastem, Inc., (NASDAQ: VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients.

When it comes to combatting cancer, we realize there are no “one size fits all” treatment approaches. We understand that every cancer lives in an intricate and complex microenvironment, creating significant unmet needs which must be addressed. It’s why we remain open to new ideas but selectively pursue science with the potential to make a significant impact for physicians, patients and their caregivers.

Our Pipeline

We are concentrating on a portfolio of small molecule drugs designed to inhibit critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) pathways.

Our product candidates are designed to modulate the local tumor microenvironment and enhance anti-tumor immunity. For more information, please visit www.verastem.com.

<table>
<thead>
<tr>
<th>DUVELISIB (PI3K DELTA/PI3K GAMMA INHIBITOR)</th>
<th>PHASE 1/1B</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>COLLABORATOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Relapsed/Refractory CLL/PLL</td>
<td>DUO™ Complete, in long-term follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomized open-label vs. ofatumumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refractory INHL</td>
<td>DYNAMO™ Complete, in long-term follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-arm, monotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed/Refractory PTCL</td>
<td>PRIMO™ Enrolling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single-arm, monotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1st line, younger CLL/PLL patients*</td>
<td>Enrolling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single arm, with FCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed/Refractory T Cell lymphoma*</td>
<td>In long term follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With Ramucirumab or Bortezomib</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed/Refractory CLL/PLL*</td>
<td></td>
<td>Enrolling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With Venetoclax</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEFACITINIB (FAK INHIBITOR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSCLC, Pancreatic, Mesothelioma*</td>
<td>Enrolling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With pembrolizumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic, relapsed*</td>
<td>Dose-escalation complete; in expansion phase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With pembrolizumab + gemcitabine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advanced Solid Tumors*</td>
<td>Dose-escalation complete; in expansion phase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With RAF/MEK Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carboplatin Resistant Ovarian*</td>
<td>Dose-escalation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With Platinum + Taxane</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Investigator-Sponsored Trial (IST)

These studies are investigating treatments or outcomes that have not received approval from a Health Authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a Health Authority.

Our Leadership

EXECUTIVE LEADERSHIP
Robert Forrester
President/CEO/Director
Daniel Paterson
Chief Operating Officer
Joseph Lobacki
Chief Commercial Officer
Steven Bloom
Chief Strategy Officer
Hagop Youssoufian, MSc, M.D.
Head, Medical Strategy
Jonathan Pachter, Ph.D.
Chief Scientific Officer
Cathy Carew
Chief People & Organizational Strategy Officer
Sean Flynn
VP and General Counsel
Rob Gagnon
Chief Financial Officer

BOARD OF DIRECTORS
Michael Kauffman, M.D., Ph.D.
Lead Director
CEO Karyopharm (KPTI), former CMO Onyx
Timothy Barberich
Former CEO/Chair Sepracor (SEPR)
Eric Rowinsky, M.D.
CSO ClearPath, former CMO ImClone Erbitux, Taxotere, Tarceva
Bruce Wendel
CSO Hepalin USA, former CEO Abraxis Bioscience
Alison Lawton
Former Genzyme (now Sanofi)
Gina Consylman
CEO Ironwood
Brian Stuglik, R.Ph.
Former Chief Marketing Officer, Lilly Oncology

CLINICAL AND SCIENTIFIC ADVISORY BOARD
Robert Weinberg, Ph.D.
Co-Founder & Chairman of CSAB
Whitehead Institute/MIT
Greg I. Berk, M.D.
Former Executive/CMO, Verastem, Sideris, BIND, Intellikine, Abraxis Biosciences
Cheryl Cohen
BDO, Tokai, Protein Sciences and Vital, former CEO, Medivation
Paul Friedman, M.D.
CEO Madrigal (SNTA), former President/CEO Incyte (INCY)
Paul Friedman, M.D.
CEO Madrigal (SNTA), former President/CEO Incyte (INCY)
Lori Kunkel, M.D.
CEO Madrigal (SNTA), former President/CEO Incyte (INCY)
Edmund J. Pezalla, M.D., Ph.D.
Former VP, Pharmaceutical Policy and Strategy at Aetna, Scholar in Residence at Duke-Margolis Health Policy Center
Steve Sherwin, M.D.
UCSF, San Francisco General Hospital Director, Biogen Idec, Neurocine Biosciences, Rigel
Max Wicha, M.D.
Director, University of Michigan Comprehensive Cancer Center
Corporate Overview

Novel drug candidates targeting malignant cells both directly and through modulation of the tumor microenvironment

- NASDAQ: VSTM
- Headquarters: Needham, MA
- Incorporated: 2010

COPIKTRA™
(duvelisib)

The first approved oral inhibitor of PI3K-δ and PI3K-γ
Exclusively marketed in the US by Verastem Oncology

Full prescribing information, including BOXED WARNING and Medication Guide, is available at www.COPIKTRA.com

Investigational research & pipeline

Duvelisib program
- Ongoing clinical expansion in PTCL (FDA Fast Track Designation)
- Ongoing clinical investigation as monotherapy and in combination in multiple hematologic malignancies
- IP: COM 2030 before extensions
- Partnered in Japan and China

Defactinib program
- Investigational FAK inhibitor
- Clinical Proof-of-Concept of FAK/Immuno-Oncology combinations in 2018
- IP: COM 2028 before extensions
- Orphan Designation: Ovarian & mesothelioma in the US & EU

We’re driven by the strength, tenacity, and courage of those battling cancer –

Single minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Dedicated to improving how physicians care for their patients, and how caregivers cope with looking after a loved one or friend.

Because for us, it’s personal.